Your browser doesn't support javascript.
loading
Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.
Lindley, Anouk; Prager, Gerald; Bitzer, Michael; Burn, Timothy C; Lihou, Christine F; Croft, Elisabeth.
Afiliación
  • Lindley A; Incyte Corporation, Wilmington, DE, USA.
  • Prager G; Medical University of Vienna, Department of Internal Medicine I, Comprehensive Cancer Center Vienna, Vienna, Austria.
  • Bitzer M; Department of Internal Medicine I, Eberhard-Karls University, Tübingen, Germany.
  • Burn TC; Incyte Corporation, Wilmington, DE, USA.
  • Lihou CF; Incyte Corporation, Wilmington, DE, USA.
  • Croft E; Incyte Corporation, Wilmington, DE, USA.
Cancer Res Treat ; 56(3): 847-855, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38351684
ABSTRACT

PURPOSE:

Pemigatinib is a fibroblast growth factor receptor-2 (FGFR2) inhibitor approved for use in patients with previously treated cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements. This ongoing global Expanded Access Program (EAP) allows physicians in regions where pemigatinib is not commercially available to request pemigatinib for patients with locally advanced or metastatic CCA who, in the physician's opinion, could benefit from pemigatinib treatment. MATERIALS AND

METHODS:

Eighty-nine patients from Europe, North America, and Israel were treated from January 2020 through September 2021.

RESULTS:

Patients had FGFR gene fusions (68.5%), rearrangements (12.4%), translocations (5.6%), amplifications (2.2%), and other alterations (11.2%). Median duration of treatment in the EAP was 4.0 months (range, 0.1 to 13.6 months). The most frequently reported adverse event (AE) was hyperphosphatemia (22.5%); the most common serious AE was cholangitis (3.4%). Treatment discontinuation was associated with reports of AEs for seven patients (7.9%). AEs associated with pemigatinib were consistent with those observed in clinical trials.

CONCLUSION:

Efficacy was not assessed in this EAP. However, some patients remained on treatment for up to a year, suggesting that they observed a benefit from treatment. Patients with CCA should undergo molecular testing to identify those who could benefit from targeted treatments such as pemigatinib.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Colangiocarcinoma / Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Res Treat Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación:
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Colangiocarcinoma / Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Res Treat Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: